Benzinga | Jul 20, 2020 06:35AM EDT

HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Raises Price Target to $62

HC Wainwright & Co. analyst Ed Arce maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target from $45 to $62.